Loading...
Market
Story
GSK's Nucala Shows Positive Results in Phase III COPD Trial
Sep 6, 2024, 07:56 AM
GSK's asthma drug Nucala has shown positive results in a phase III late-stage trial for treating chronic obstructive pulmonary disease (COPD), also known as smoker's lungs. The British drugmaker announced on Friday that Nucala met the main goal of the trial, potentially opening up a new avenue of growth for the medicine. This development comes after an FDA rejection in 2018, and GSK is now preparing to file Nucala for COPD again, armed with the new phase III data. The trial results indicate that the drug can reduce COPD attacks, which may benefit patients with this chronic lung condition.
View original story
Similar markets
Under $500 million • 33%
$500 million - $1 billion • 33%
Over $1 billion • 33%
Under $1 billion • 33%
$1 billion - $2 billion • 33%
Over $2 billion • 33%
Achieves blockbuster status in 2025 • 25%
Achieves blockbuster status in 2026 • 25%
Achieves blockbuster status in 2027 • 25%
Does not achieve blockbuster status by end of 2027 • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Less than $1 billion • 25%
$1 billion - $2 billion • 25%
$2 billion - $3 billion • 25%
More than $3 billion • 25%
Successful market introduction • 25%
Delayed market introduction • 25%
Project discontinued • 25%
Acquisition divested • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Less than $100 million • 25%
$100 million to $500 million • 25%
$500 million to $1 billion • 25%
More than $1 billion • 25%